National Cancer Institute (NCI): Lymphoma trials

The registry lists 322 Lymphoma studies with National Cancer Institute (NCI) as lead sponsor. 13 are open to participants now and 126 have results posted.

Early Phase 1 2Phase 1 166Phase 2 161Phase 3 4No phase 25(a study in two phases counts in both)

Studies

Page 3 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT00377104Phase 1
• Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LymphomaCompletedNCT00363272Phase 1
• PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomaTerminatedNCT00354185Phase 1
• Agriculture Health StudyActive, not recruitingNCT00352924
• PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasCompletedNCT00348985Phase 1
• Interdisciplinary Case-Control Study of Non-Hodgkin's LymphomaCompletedNCT00341952
• Genome Expression in Lymphoma, Leukemia and Multiple MyelomaCompletedNCT00339963
• Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1CompletedNCT00339638
• CDDO to Treat Solid Tumors and LymphomasCompletedNCT00322140Phase 1
• Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaTerminatedNCT00301795Phase 2
• 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00293345Phase 1
• Sorafenib in Treating Patients With Recurrent Non-Hodgkin's LymphomaCompletedNCT00278382Phase 2
• Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver FunctionCompletedNCT00275093Phase 1
• Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00275080Phase 1
• Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion LymphomaCompletedNCT00217503Phase 2
• Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or LeukemiaCompletedNCT00217412Phase 1
• Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionCompletedNCT00118170Phase 1
• Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00109824Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic CancerTerminatedNCT00103272Phase 1
• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasCompletedNCT00101270Phase 1
• SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's LymphomaTerminatedNCT00101244Phase 1
• Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaTerminatedNCT00101205Phase 1
• MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or LymphomasCompletedNCT00098891Phase 1
• Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTerminatedNCT00096005Phase 1
• 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomasCompletedNCT00089271Phase 1
• Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00089154Phase 2
• Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00086944Phase 1/2
• CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT00086840Phase 2
• LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or LymphomaCompletedNCT00085150Phase 1
• Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00082966Phase 2
• Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsCompletedNCT00082784Phase 1
• S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's LymphomaTerminatedNCT00080847Phase 2
• FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's LymphomaTerminatedNCT00079443Phase 2
• Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00079378Phase 1
• FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00077194Phase 2
• Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00077155Phase 1
• Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell LymphomaCompletedNCT00070447Phase 2
• Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00068315Phase 1
• Voriconazole in Preventing Fungal Infections in Children With Neutropenia After ChemotherapyCompletedNCT00066599Phase 2
• Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisorderCompletedNCT00064246Phase 1/2
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
• Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or LymphomaTerminatedNCT00060112Phase 1
• Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT00058461Phase 2
• Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell TransplantationCompletedNCT00058305Phase 2
• Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell LymphomaCompletedNCT00058227Phase 1
• Bortezomib in Treating Patients With Advanced Cancer and Kidney DysfunctionCompletedNCT00054483Phase 1
• Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis FungoidesTerminatedNCT00052377Phase 1/2
• UCN-01 and Prednisone in Treating Patients With Solid Tumors or LymphomaCompletedNCT00045500Phase 1
• Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic CancerActive, not recruitingNCT00039676
• Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory LymphomaTerminatedNCT00036855Phase 1
• CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's LymphomaCompletedNCT00033267Phase 2
• Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's LymphomaCompletedNCT00026910
• Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00026182Phase 2
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaWithdrawnNCT00024115Phase 1
• Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic LeukemiaTerminatedNCT00022971Phase 1
• Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00022581Phase 2
• Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related LymphomaCompletedNCT00022555Phase 1
• Caspofungin Acetate in Treating Children With Fever and NeutropeniaCompletedNCT00020527Not applicable
• Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular LymphomaCompletedNCT00020462Phase 1
• Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or LymphomaCompletedNCT00020111Phase 1
• Analysis of Genes Present in Cutaneous T-cell Lymphoma CellsCompletedNCT00020072Not applicable
• UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or LeukemiaCompletedNCT00019838Phase 1
• Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaTerminatedNCT00019708Phase 1
• Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic CancerCompletedNCT00019656Phase 1
• Flavopiridol in Treating Patients With Refractory CancerCompletedNCT00019344Phase 1
• Depsipeptide in Treating Patients With Solid TumorsCompletedNCT00019318Phase 1
• Monoclonal Antibody Therapy in Treating Patients With LeukemiaCompletedNCT00019227Phase 1/2
• Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00017472Phase 1
• Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00017381Early Phase 1
• S0108 Bevacizumab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00016094Phase 2
• Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT00015912Phase 2
• Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic MalignanciesCompletedNCT00013533Early Phase 1
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or LymphomasCompletedNCT00012181Phase 1
• Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerCompletedNCT00010192Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory LymphomaCompletedNCT00007956Phase 1
• Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00006473Phase 2
• BMS-247550 in Treating Patients With Advanced CancersCompletedNCT00006221Phase 1
• Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00006102Phase 2
• 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell LymphomaTerminatedNCT00005982Phase 2
• Tipifarnib in Treating Patients With Advanced Hematologic CancerCompletedNCT00005967Phase 1
• 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell LymphomaTerminatedNCT00005950Phase 2
• Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous TreatmentCompletedNCT00005811Phase 2
• Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or LeukemiaTerminatedNCT00005786Not applicable
• 506U78 in Treating Patients With LymphomaCompletedNCT00005080Phase 2
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or SarcomaCompletedNCT00004241Phase 1
• Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced CancerCompletedNCT00004189Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's LymphomaCompletedNCT00004101Phase 1
• Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or LymphomaCompletedNCT00003970Phase 1
• 506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaCompletedNCT00003837Not applicable
• O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell LymphomaTerminatedNCT00003613Phase 1
• Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's LymphomaCompletedNCT00003595Phase 3
• Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's LymphomaCompletedNCT00003575Phase 2
• 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT00003545Phase 2
• Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
• Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the PelvisCompletedNCT00003368Phase 1
• Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's DiseaseCompletedNCT00003210Phase 2
• Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's LymphomaCompletedNCT00003204Phase 3
• Bryostatin and Vincristine in B-Cell MalignanciesCompletedNCT00003166Phase 1
• Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell LymphomaCompletedNCT00003039Phase 2